Coronary/Structural Heart

New Study Shows That Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality Associated with Transcatheter Aortic Valve Replacement (TAVR)

SANTA ROSA, Calif.–(BUSINESS WIRE)–Claret Medical® today announced publication of a new study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions that underscores the role of the Sentinel Cerebral Protection System (CPS) in significantly reducing the early occurrence of stroke associated with transcatheter aortic valve replacement (TAVR). The study […]

BioVentrix Announces The 1st Revivent TC TransCatheter Ventricular Enhancement Procedure For Ischemic Cardiomyopathy Treatment At The University Heart Center Zurich In Switzerland

SAN RAMON, Calif., and ZURICH, Sept. 18, 2017 /PRNewswire/ — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System at the University Hospital Zurich in Switzerland. A team led by Prof. Francesco Maisano, co-director […]

Cardiosolutions Key U.S. Patent Application For Adjustable “Spacer” Technology To Treat Heart Valve Regurgitation Receives Notice Of Allowance

WEST BRIDGEWATER, Mass., Sept. 18, 2017 /PRNewswire/ — Cardiosolutions, Inc., today announced that the United States Patent and Trademark Office has issued a Notice of Allowance to grant a key US patent covering the company’s proprietary ‘spacer’ technology for the treatment of regurgitation in incompetent heart valves. The allowed patent underlies the […]

BioCardia’s CardiAMP Heart Failure Trial Design To Be Presented At Texas Heart Institute International Symposium On Cardiovascular Regenerative Medicine

HOUSTON & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the trial design for its pivotal Phase III CardiAMP Heart Failure Trial will be presented tomorrow during the “Heart Failure: The Big Target for CV Regenerative Therapy […]

Vasorum Launches Celt ACD® Second Generation Vascular Closure Device in the USA

DUBLIN, Ireland, September 12, 2017 /PRNewswire/ — Vasorum Ltd, following FDA approval of its PMA supplement, the developer and manufacturer of the novel Celt ACD®vascular closure device has added a 7F sized Celt ACD® device to its Celt ACD® 6F and Celt ACD® 5F size range in the USA. Celt ACD® is indicated for arterial puncture closure in […]

Neovasc Provides Tiara™ Clinical Update

VANCOUVER, Sept. 12, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western […]

LivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the publication of the analysis, “The Perceval® Sutureless Aortic Valve: Review of Outcomes, Complications and Future Direction,” by Powell, Pelletier, Chu, Bouchard, Melvin and Adams in the latest issue of Innovations1. The literature review, which included […]

Corindus Announces First Patient Enrolled in PRECISION GRX Registry

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced first patient enrollment in the PRECISION GRX Registry, a post-market study to continue market surveillance of the Company’s second generation CorPath GRX System. The PRECISION GRX Registry will include up to 25 sites […]

Micro Interventional Devices Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA Technology

NEWTOWN, Pa., Sept. 7, 2017 /PRNewswire/ — Micro Interventional Devices, Inc.(MID) has successfully completed the first in human tricuspid valve bicuspidization procedure utilizing its MIA (Minimally Invasive Annuloplasty) technology.  The successful bicuspidization resulted in a 34.5% reduction in valve area, reducing the patient’s tricuspid regurgitation from severe/moderate to trace. The patient was the […]